FindTrial
Sign In

Effectiveness and safety of hydroxychloroquine sulfate in the preventive treatment of novel coronavirus pneumonia (COVID-19)

Effectiveness and safety of hydroxychloroquine sulfate in the preventive treatment of novel coronavirus pneumonia (COVID-19)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000031174
Enrollment
Unknown
Registered
2020-03-23
Start date
2020-03-23
Completion date
Unknown
Last updated
2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Experimental group vs control group:Hydroxychloroquine versus Placebo

Sponsors

Shanghai Public Health Clinical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Healthy subjects with negative COVID-19 nucleic acid test and antibody test; (2) Aged 18-70 years; (3) Sign the informed consent and volunteer to participate in this study.

Exclusion criteria

Exclusion criteria: (1) Patients allergic to chloroquine and hydroxychloroquine; (2) Women during pregnancy; (3) Patients with heart, lung, kidney, brain, blood and other important organs with severe diseases accompanied by insufficiency; (4) Patients with retinal disease, hearing loss or hearing loss; (5) Patients with severe neurological and mental illness; (6) Subjects who the investigator believes cannot complete the study as required, or is not suitable to participate in the study.

Design outcomes

Primary

MeasureTime frame
COVID-19 Nucleic acid;—

Countries

China

Contacts

Public ContactLu Shuihua

Shanghai Public Health Clinical Center

tuberculosis@shphc.org.cn+86 18930811818

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026